Cognition Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
/ 
Frequently asked questions
To buy Cognition Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Cognition Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Cognition Therapeutics Inc. is CGTX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Cognition Therapeutics Inc. has its primary listing on NASDAQ. You can trade Cognition Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Cognition Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Cognition Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Cognition Therapeutics Inc..